

An Open-Label, Multicenter, First-In Human Clinical Trial of PTX-102 mRNA Vaccine in Patients with Advanced Solid Tumors

Project duration: 2025-3-14 to 2027-3-31

Targeted cancer type:

Various cancers

This research team plans to evaluate the safety and patient immune data arising from a clinical trial examining PTX-102, an innovative mRNA cancer vaccine against solid tumours.

Project value:

\$11,048,300

BioCanRx Contribution:

\$998,300

Key Investigators:

Project Lead:

Dr. Amit Oza



1

Partner



Biotherapeutic:

mRNA vaccine

About the project:

The research centers on PTX-102, an innovative mRNA vaccine designed to boost the immune system's ability to fight various cancers, including ovarian, melanoma, and lung cancer. PTX-102 works by instructing the body to recognize and attack specific markers found on cancer cells, while sparing healthy tissues. This approach aims to generate a strong and targeted immune response, potentially reducing the tumor's capacity to grow and spread. The primary goal of the study is to evaluate the safety of PTX-102 in a small group of patients and determine the optimal dose for use in future clinical trials. Researchers will closely monitor the

patients to assess how effectively the vaccine activates the immune system and to identify any early signs of its potential to control cancer progression. This study will also explore immune response markers, providing insights into how the vaccine interacts with the body's natural defenses. This research is closely aligned with BioCanRx's mission to advance promising cancer immunotherapies. PTX-102 offers the potential to provide a new therapeutic option for patients who do not respond well to current treatments, addressing an important unmet need in oncology.

Industry Collaborator:
Providence Therapeutics,
Calgary, AB
Dr. Natalia Martin Orozco

Research:
Princess Margaret Cancer Centre,
Toronto, ON
Dr. Amit Oza, Dr. Pamela Ohashi,
Dr. Stephanie Lheureux,
Dr. Ben Wang, Dr. Ana Veneziani,
Dr. Marcus Butler

ON Institute for Cancer Research,
Toronto, ON
Dr. Trevor Pugh

Partner:

Providence Therapeutics Inc

Total Pledged Partner Contributions: \$10,050,000

Total Pledged Matched Contributions: \$10,050,000

Key Deliverables

1. Patient enrollment
2. Assessment of Phase 1 MTD and recommended phase 2 dose
3. Publication of clinical results



The power to kill cancer lies within us. Let's tell our bodies how.